Recruiting
Neoplasm
RecruitingStudy of ALE.
InvestigationalNo placebo
Study of ALE.
InvestigationalNo placebo
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ALE.P03
- Sponsor:Alentis Therapeutics AG
Back to ItalyClinical trials in Milan – page 31
2 423 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Milan at a glance
2 423
clinical trials
- Research sites15
Recruiting
Non-small cell lung cancer
RecruitingA Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
Registered drugNo placebo
A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:DocetaxelHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Pfizer Inc.
Recruiting
Breast cancer+3
RecruitingA Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment
Registered drugNo placebo
A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+2
- Substances:AbemaciclibGiredestrant
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Genentech Inc.
Recruiting
Cytomegalovirus infection+1
RecruitingA Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment
Registered drugNo placebo
A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment
Registered drugNo placebo
- Disease:Cytomegalovirus infectionAllogenic stem cell transplantation
- Substances:Maribavir
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Maribavir
- Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare
Recruiting
Hormone-refractory prostate cancer
RecruitingA Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment
Investigational
A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment
Investigational
- Disease:Hormone-refractory prostate cancer
- Substances:JNJ-78278343
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:JNJ-78278343
- Sponsor:Janssen Cilag International
Recruiting
Cardiac failure
RecruitingA Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care
Registered drugNo placebo
A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care
Registered drugNo placebo
- Disease:Cardiac failure
- Substances:BisoprololCandesartan+20
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bisoprolol
- Sponsor:Policlinico San Donato S.p.A.
Recruiting
Diabetes mellitus
RecruitingA Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes
Investigational
A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes
Investigational
- Disease:Diabetes mellitus
- Substances:Teplizumab
Countries:Italy
Italy- Participants:0–17 years · 18–64 years
- Substances:Teplizumab
- Sponsor:Sanofi-Aventis Recherche & Developpement
Recruiting
Endometrial cancer metastatic
RecruitingA Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
- Disease:Endometrial cancer metastatic
- Substances:AZD8205Doxorubicin+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:AZD8205
- Sponsor:AstraZeneca AB
Recruiting
Hypertrophic cardiomyopathy+1
RecruitingA study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
- Disease:Hypertrophic cardiomyopathyCardiomyopathy
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Sponsor:Imbria Pharmaceuticals Inc.
Recruiting
Clear cell renal cell carcinoma
RecruitingA Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer
Registered drug
A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer
Registered drug
- Disease:Clear cell renal cell carcinoma
- Substances:AB521Cabozantinib+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:AB521
- Sponsor:Arcus Biosciences Inc.
Recruiting
Non-small cell lung cancer+1
RecruitingA Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation
Registered drugNo placebo
A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation
Registered drugNo placebo
- Disease:Non-small cell lung cancerLung neoplasm malignant
- Substances:CarboplatinCisplatin+3
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Merck Sharp & Dohme LLC
Recruiting
Breast cancer+2
RecruitingA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
Registered drugNo placebo
A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:CapivasertibFulvestrant+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Capivasertib
- Sponsor:Relay Therapeutics Inc.
Other cities in Italy
The busiest research cities in the country
Clinical research in Milan
What the registry says about research in the country
01 Oncology Research
Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.
- Metastatic Colorectal Cancer Treatment
- Breast Cancer Prevention Strategies
- Advanced Solid Malignancies
Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.
02 Neurological Disorders
Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.
- Frontotemporal Dementia
- Parkinson's Disease
- Migraine Treatment
Focus on developing targeted therapies and understanding disease mechanisms.
03 Immunology and Infectious Diseases
Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.
- Immune Thrombocytopenia
- RSV Prevention
- HIV Prevention
Emphasis on developing novel preventive strategies and therapeutic solutions.